Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatic Niemann-Pick C1-Like 1 exacerbates non-alcoholic fatty liver disease by re-absorbing specific biliary oxysterols
Yoshihide Yamanashi, Tappei Takada, Yusuke Tanaka, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113877-113877
Open Access | Times Cited: 9

Showing 9 citing articles:

Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism
Xiaoxi Feng, Rutong Zhang, Zhenye Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 5
The Cross-Talk Between the Peripheral and Brain Cholesterol Metabolisms
Ilinca Săvulescu-Fiedler, Luiza-Roxana Dorobantu-Lungu, Şerban Dragosloveanu, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 2, pp. 115-115
Open Access
Potential function of hepatic Niemann–Pick C1-like 1: cholesterol homeostasis regulation of the canalicular lipid bilayer membrane
Hongtan Chen, Pingfan Mo, Guoqiang Xu
Gastroenterology report (2025) Vol. 13
Open Access
Mechanism and therapeutic potential of liver injury induced by cholesterol-associated proteins
Yourong Zhou, Yashi Cao, Yiming Yin, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease
Shendong Wang, Junhao Yin, Zhaojun Liu, et al.
Life Sciences (2024) Vol. 359, pp. 123211-123211
Closed Access | Times Cited: 3
Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions
X. Li, Meng Li
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 1073-1073
Open Access | Times Cited: 2
Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study
Hao Dong, Rong Chen, Jiafeng Wang, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 9, pp. 1599-1604
Closed Access | Times Cited: 1
Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?
Panagiotis Anagnostis, Vasilios Kotsis, Maciej Banach, et al.
Metabolites (2023) Vol. 13, Iss. 2, pp. 145-145
Open Access | Times Cited: 3
Downregulation of CYP7B1 caused by lipotoxicity associates with the progression of non-alcoholic steatohepatitis
Yuichi Watanabe, Kyohei Kinoshita, Napatsorn Dumrongkulchart, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top